Equity Research Report: FDC Limited
Date: February 7, 2026
Analyst: Gemini (Stock Analysis AI)
Current Market Price (CMP): ₹368 – ₹375 (Approx)
1️⃣ Business Model & Work
- Core Business: FDC Limited (Food and Drug Control) ek purani aur trusted Indian pharma company hai jo mainly Domestic Formulations (India market) par focus karti hai. Ye Oral Rehydration Salts (ORS) aur Antibiotics ke market leader hain.
- Key Brands (The Moat):
- Electral: India ka synonym for ORS (WHO formula). Ye inka “Cash Cow” product hai.
- Enerzal: Energy drink segment me strong brand.
- Zifi: Antibiotic segment (Cefixime) me market leader.
- Revenue Mix (Approx):
- Domestic (India): ~84-85% (Main revenue source).
- Exports: ~15-16% (US, UK, South Africa).
- Niche Focus: Unlike other pharma giants jo US generics par heavy depend karte hain, FDC ka main focus India me Lifestyle & Acute therapy (ORS, Ophthlamics, Antibiotics) par hai.
2️⃣ Industry & Sector Analysis
- Sector Status: Defensive & Steady. Pharma sector domestic demand par chalta hai.
- Current Trend (2026):
- Domestic Slowdown: FY26 me Indian Pharma Market (IPM) ki volume growth thodi soft rahi hai, jiska asar FDC par bhi dikh raha hai.
- Climate Impact: Electral/Enerzal ki sales “Summer Season” aur “Flu Season” par bahut depend karti hain. Changing weather patterns demand ko volatile bana rahe hain.
- Competition: Cipla (ORS competitor), Mankind Pharma, Alkem Labs (Antibiotics).
3️⃣ Latest Financial Performance (Q3 FY26 – Dec 2025)
⚠️ Data Source: Based on latest results announced Feb 5, 2026.
| Metric | Q3 FY26 (Dec ’25) | Q3 FY25 (Dec ’24) | YoY Change | Comment |
| Revenue | ₹465 Cr | ₹464 Cr | ↔️ Flat | Domestic sales fell 5.2%, Exports surged 55% |
| EBITDA | ₹52 Cr | ₹47 Cr | 🔼 12.1% | Operational efficiency improved margins |
| EBITDA Margin | 11.2% | 10.1% | 🔼 Improve | Cost control measures working |
| Net Profit (PAT) | ₹28 Cr | ₹37 Cr | 🔻 23.6% | Impacted by Exceptional Items |
| EPS | ₹1.74 | ₹2.28 | 🔻 | Low earnings this quarter |
- Key Insight: Domestic business (Zifi/Electral) me -5.2% ki de-growth aayi hai jo chinta ka vishay hai. Halanki, Export business ne +55% jump lekar isko balance karne ki koshish ki.
- Exceptional Item: Company ne ₹21 Cr ka one-time kharcha book kiya hai due to “New Labour Codes” implementation. Iske bina profit stable hota.
- Dividend: Board ne ₹5 per share ka Interim Dividend declare kiya hai (Record Date: Feb 11, 2026).
4️⃣ Management & Shareholding (Dec 2025)
| Category | Holding (%) | Observation |
| Promoters | 69.66% | Very High & Stable. Chandavarkar family control karti hai. |
| FIIs | 2.32% | Low interest from foreign investors. |
| DIIs / Mutual Funds | 6.21% | Moderate. HDFC Small Cap & Tata MF jaise funds invested hain. |
| Public | 21.75% | Retail participation significant hai. |
- Track Record: Management conservative hai. Wo aggressively acquisitions nahi karte, balki Share Buybacks ke through cash return karna pasand karte hain (Regular buybacks in past).
5️⃣ Valuation (Latest Market Data)
- Current P/E (TTM): ~26x – 28x.
- Peer Comparison:
- Cipla: ~28x P/E.
- J.B. Chemicals: ~35x P/E.
- Eris Lifesciences: ~30x P/E.
- Fair Value Check:
- FDC apne peers ke comparison me “Fairly Valued” hai. Sasta nahi hai kyunki growth (Revenue CAGR) pichle 3 saal se single digit me hai.
- Market ise “Cash Cow” ki tarah treat karta hai, growth machine ki tarah nahi.
6️⃣ Future Growth Triggers (3–5 Years)
- Capacity Expansion: Sinnar Plant me ₹140 Cr ka expansion (Liquid Oral facility) chal raha hai jo FY27 tak full revenue contribute karega.
- Export Revival: USFDA se naye approvals (jaise recent Pilocarpine Eye Drops approval in Oct 2025) export revenue ko boost denge.
- New Launches: Foods & Nutraceuticals segment me naye variants launch karke company dependency Electral se kam karna chahti hai.
7️⃣ Present Situation & Outlook
- Current Phase: Consolidation/Correction. Stock apne 52-week high (~₹527) se correct hokar ₹370 ke aas-paas ghoom raha hai. Recent Q3 results (Flat Revenue) ne sentiment weak kiya hai.
- Short-Term: Q4 (Jan-Mar) usually seasonal weak quarter hota hai FDC ke liye (sardiyon me ORS/Drinks kam bikte hain). Price range-bound reh sakta hai.
- Long-Term: Company Debt-free hai aur cash rich hai. Agar Domestic sales wapas positive hoti hain, to stock recover karega.
8️⃣ Risk & Red Flags
- Product Concentration: FDC ka revenue majorly Electral aur Zifi par nirbhar hai. Agar koi naya competitor (jaise Cipla ka Prolyte) market share le gaya, to bada risk hai.
- Government Price Control (NLEM): Inke key drugs (Essential medicines) price control list me aate hain, jisse margins par cap lag jata hai.
- USFDA Regulatory Risk: Export business USFDA inspections par depend karta hai. Waluj/Goa plants par koi negative observation aayi to export gir sakta hai.
9️⃣ Final Verdict
- Summary: FDC ek “Slow & Steady” dividend-paying stock hai, koi high-growth rocket nahi. Balance sheet strong hai (Zero Debt), lekin sales growth abhi missing hai.
- For Conservative Investors: HOLD / BUY on Dips. Agar aapko FD se behtar return aur safety chahiye, to ye stock suitable hai. Dividend yield (~1.3% – 1.5%) aur Buybacks returns boost karte hain.
- For Aggressive Investors: AVOID. Revenue growth stagnant hai. Market me pharma sector me doosre players (like Mankind or JB Chem) hain jo fast grow kar rahe hain.
- Target Range: Valuation support ₹350 ke paas strong hai. Upside capped lag raha hai jab tak revenue growth double-digit me wapas nahi aati.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.